In this article we review the glucagon like peptide 1 receptor agonist (GLP-1) medications and discuss how to approach using them for weight loss and management in non-diabetic patients.
Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1 drugs like Ozempic and Wegovy are ...
To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity.
GLP-1 receptor agonists are medications designed to mimic this hormone. They were originally developed to treat type 2 diabetes, but clinicians observed that many patients also experienced significant weight loss.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of obesity. To assess the weight-loss effects of GLP-1RAs in the treatment of patients with overweight or obesity without diabetes. This is a systematic review with meta-analysis and trial sequential analysis.
As we can see from the illustration, Glp-1 Receptor Agonist Weight Loss Conversation has many fascinating aspects to explore.
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.
